Literature DB >> 3680605

Reinduction of neuroleptic malignant syndrome by lithium.

V L Susman1, G Addonizio.   

Abstract

The psychopharmacologic management of psychotic patients who have had neuroleptic malignant syndrome poses a dilemma for clinicians. Neuroleptic malignant syndrome can recur when neuroleptics are readministered, but there are equal numbers of reports of safe resumption of neuroleptic treatment in patients who have had the syndrome. In an effort to avoid reexposure to neuroleptics, the authors treated two bipolar patients who were clinically recovered from episodes of neuroleptic malignant syndrome with lithium alone. Both patients rapidly developed recurrent neuroleptic malignant syndrome after only 300 and 1,200 mg of lithium, respectively. Possible pathogenetic mechanisms are reviewed, although a definitive explanation for such a sudden and dramatic toxic effect is not available.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680605

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  4 in total

Review 1.  Neuroleptic malignant syndrome--follow-up study.

Authors:  P Buckley; A Freyne; A McCarthy; C Larkin
Journal:  Ir J Med Sci       Date:  1991-02       Impact factor: 1.568

2.  Neuroleptic malignant syndrome and lithium carbonate.

Authors:  S Fava; A C Galizia
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

3.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12

Review 4.  Neuroleptic malignant syndrome. Recognition, prevention and management.

Authors:  V R Velamoor
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.